A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”
PTC Therapeutics Inc Patent Filing for Huntington’s Disease Treatment
Share this article According to GlobalData’s company profile on PTC Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. PTC Therapeutics‘s